ライフサイエンスコーパス: community-acquired infection

1 versus 16%; P < 0.001) than in patients with community-acquired infection.

2 us is a leading cause of both nosocomial and community-acquired infection.

3 devices might be responsible for the rise of community acquired infections.

4 timicrobial resistance, especially regarding community-acquired infections.

5 the etiological agent of many hospital- and community-acquired infections.

6 ial resistance in both hospital-acquired and community-acquired infections.

7 hypervirulent strains associated with severe community-acquired infections.

8 us is now one of the key causative agents of community-acquired infections.

9 g our ability to treat routine hospital- and community-acquired infections.

10 thogen and a leading cause of nosocomial and community-acquired infections.

11 ria, and its presence in both nosocomial and community-acquired infections.

12 us, which is a major cause of nosocomial and community-acquired infections.

13 vant pathogens responsible for hospital- and community-acquired infections.

14 d to distinguish health-care-associated from community-acquired infections.

15 he number of methicillin-resistant S. aureus community-acquired infections.

16 or causative agent of numerous hospital- and community-acquired infections.

17 us is a major cause of severe nosocomial and community-acquired infections.

18 lity, have traditionally been categorized as community-acquired infections.

19 human pathogen causing hospital-acquired and community-acquired infections.

20 ureus is responsible for many nosocomial and community-acquired infections.

21 increasing number of serious nosocomial and community-acquired infections.

22 weeks to months, considerably faster than in community-acquired infections.

23 hours after LTCC admission so as to exclude community-acquired infections.

24 nce of nosocomial transmission compared with community-acquired infection?

25 reas in the smaller group of inpatients with community-acquired infections, 12 capsid and 9 polymeras

26 clinical indication for antibiotic use were community acquired infection (41%).

27 with shorter times to antimicrobial therapy: community-acquired infections (-53 min; p < 0.001) and h

28 17 of 31; P = 0.05); rates were similar for community-acquired infections (80% [124 of 156] versus 8

29 nclude a predisposition to opportunistic and community-acquired infections, an altered response to va

30 ains have spread throughout hospitals, while community acquired infections and other sources ensure a

31 rology, we estimated both the probability of community-acquired infection and within-household transm

32 charges) for nosocomial-acquired infections, community-acquired infections, and sepsis, respectively.

33 ra days) for nosocomial-acquired infections, community-acquired infections, and sepsis, respectively.

34 deaths) for nosocomial-acquired infections, community-acquired infections, and sepsis, respectively.

35 ions are nosocomial, but a growing number of community-acquired infections are caused by hypervirulen

36 es (surgical prophylaxis, broad-spectrum for community-acquired infections, broad-spectrum for hospit

37 phylococcus aureus (MRSA) strains that cause community-acquired infections (CA-MRSA).

38 Community-acquired infections (CAIs) were cultures posit

39 s and clinical data were collected daily for community-acquired infections (CAIs).

40 A parallel phenomenon of severe community-acquired infections caused by 'hypervirulent'

41 Community-acquired infections caused by methicillin-resi

42 Of the bacteria typically responsible for community-acquired infections, clarithromycin-resistant

43 us aureus is a major cause of nosocomial and community-acquired infections for which a vaccine is gre

44 cephalosporins cannot be recommended even in community-acquired infection in our cirrhotic population

45 Melioidosis is an important cause of community-acquired infection in Southeast Asia and north

46 ic characteristics have been responsible for community-acquired infections in France and Switzerland.

47 antibiotics but are highly virulent, causing community-acquired infections in healthy individuals.

48 n humans, are now emerging as agents of both community-acquired infections in humans as well as hospi

49 he magnitude and term of morbidity of acute, community-acquired infections in immune competent patien

50 influenza virus (PIVi) infections are common community-acquired infections in lung transplant recipie

51 changed markedly due to strong increases in community-acquired infections in successive periods of v

52 Staphylococcus aureus, is a major source of community-acquired infections in the USA, Canada, and Eu

53 has an appropriate spectrum of activity for community-acquired infections, including those caused by

54 auses toxin-mediated nosocomial diarrhea and community-acquired infections; no preventive vaccine is

55 They are spread by community-acquired infection of free virus (acqHHV6A/6B)

56 anges to antibiotic treatment guidelines for community-acquired infections of the upper and lower res

57 infection (OR, 2.752 [95% CI, 1.100-6.886]), community-acquired infection (OR, 10.432 [95% CI, 3.623-

58 rmpA (OR, 17.398 [95% CI, 4.224-71.668]) and community-acquired infection (OR, 6.844 [95% CI, 1.905-2

59 Antibiotics for community-acquired infection should treat aerobic and an

60 ntibiotic-resistant bacteria responsible for community-acquired infections such as Salmonella spp, Ca

61 e its being a leading cause of nosocomal and community-acquired infections, surprisingly little is kn

62 ll death rate was 13%, ranging from 5% after community-acquired infections to 25% after infections ac

63 th Pneumocystis by cohabitation, to resemble community-acquired infection, underwent lung assessments

64 In community-acquired infections, we observed substantial r

65 Community acquired infection were most common clinical c

66 , concurrent InfA strains from patients with community-acquired infection were included.

67 Approximately 50% of community-acquired infections were streptococcal, and 20

68 in an inpatient stay are considered to have community-acquired infection, while those developing sym

69 ticipants and their risk for colonisation or community-acquired infection with priority bacterial pat

70 virulent Klebsiella pneumoniae causes severe community-acquired infections, with its mucoid phenotype

71 , has caused extensive hospital-acquired and community-acquired infections worldwide.

72 ged and caused serious hospital-acquired and community-acquired infections worldwide.